{"id":"rp-g28","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (bloating, gas, diarrhea)"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RP-G28 works by selectively promoting the growth of beneficial commensal bacteria in the gastrointestinal tract, thereby restoring a healthier microbiome composition. This microbiome modulation is intended to improve intestinal barrier function, reduce systemic inflammation, and enhance metabolic parameters without requiring systemic absorption of the drug itself.","oneSentence":"RP-G28 is a non-systemic oral therapeutic that modulates the gut microbiome to improve metabolic and immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:55.329Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperammonemia in urea cycle disorder patients"}]},"trialDetails":[{"nctId":"NCT03597516","phase":"PHASE3","title":"Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance","status":"COMPLETED","sponsor":"Ritter Pharmaceuticals, Inc.","startDate":"2018-06-26","conditions":"Lactose Intolerance","enrollment":557},{"nctId":"NCT03563846","phase":"PHASE1","title":"Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects","status":"COMPLETED","sponsor":"Ritter Pharmaceuticals, Inc.","startDate":"2018-03-09","conditions":"Lactose Intolerance","enrollment":14},{"nctId":"NCT02673749","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance","status":"COMPLETED","sponsor":"Ritter Pharmaceuticals, Inc.","startDate":"2016-02","conditions":"Lactose Intolerance","enrollment":377},{"nctId":"NCT01113619","phase":"PHASE2","title":"Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance","status":"COMPLETED","sponsor":"Ritter Pharmaceuticals, Inc.","startDate":"2011-04","conditions":"Lactose Intolerance","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["galactic-oligosaccharide"],"phase":"phase_3","status":"active","brandName":"RP-G28","genericName":"RP-G28","companyName":"Ritter Pharmaceuticals, Inc.","companyId":"ritter-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RP-G28 is a treatment being studied for lactose intolerance in a Phase 3 clinical trial. The trial, NCT03597516, is evaluating the efficacy, durability, safety, and tolerability of RP-G28 compared to a placebo in patients with lactose intolerance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}